Celish FD

What's new

Mission

We carry out biotechnology-based service work for business companies. We have been involved in various research and development projects in collaboration with many companies, utilising our protein synthesis, PCR primer design and compound screening assay technologies.

As a new initiative, we are developing LISH-GENE®, an ultra-fast genetic analysis system that identifies pathogens simply and quickly on the spot. In addition, Antibody Compass®, a test that reads the early signs of ageing and disease from a single drop of blood, went on sale in July 2026. Both are core projects aimed at a society where everyone can receive appropriate healthcare and treatment with peace of mind.

Business

Integrating advanced molecular biotechnology with computational science, we provide a comprehensive range of research and development support and contract services as a trusted partner for pharmaceutical companies, medical institutions, and research organisations. From cutting-edge gene expression analysis and protein engineering to the visualisation of immune ageing and the development of next-generation diagnostic systems, we deliver end-to-end biotech solutions to drive innovation.

Specifically, we operate our core businesses based on the following advanced technologies:

• Analysis of quantitative in situ hybridisation (gene expression analysis)
• Protein synthesis
• Analysis of compound screening assays
• Computational design and modification of peptides and proteins (e.g., antibodies)
• Development of novel artificial proteins
• Diagnostic marker discovery and development of diagnostic kits and equipment
• Development of PCR primers for genetic diagnosis of infectious diseases
• Development of an ultra-fast genetic analysis system (LISH-GENE®)
• Visualisation of immune ageing and assessment of disease risks (Antibody Compass®)
• Clinical laboratory testing services
• Other collaborative research projects and contract research business

Featured Projects

Among our core businesses, the following two initiatives are the focus of our current efforts. Antibody Compass® went on sale in July 2026. For LISH-GENE®, further details will be announced as development progresses.

LISH-GENE®

An on-demand microbiome analysis system

LISH-GENE® is an on-demand microbiome analysis system that combines ultra-fast PCR with our proprietary assay kits to identify pathogens and resident microbes on the spot, in minutes. Without sending samples to an external laboratory, it aims to detect multiple targets at once with speed and high sensitivity. From infectious disease to everyday settings such as dentistry and skincare, we envision genetic analysis becoming part of daily life — so anyone can easily check the state of their own body.

Details coming soon

Antibody Compass®

Reading the early signs of ageing and disease from a single drop of blood

Antibody Compass® is a testing service that measures multiple autoantibodies from a single drop of blood taken at the fingertip, visualising the degree of immune ageing and the tendency towards chronic inflammation risk. While a standard health check looks at present abnormalities and genetic testing reveals inherited traits, Antibody Compass focuses on “the changes now unfolding within the body”. By interpreting the results from multiple angles, it gives each person the chance to rethink their health at an early stage.

Now available View the brochure (Japanese only)

Profile

Grants & Subsidies

• Chiba Industry Advancement Center
  Chiba Vitalization Grant Project (Advanced Research and Development)
  2014
• Small and Medium Enterprise Agency Chiba Secretariat, Chiba Prefectural Federation of Small Business Associations
  FY2014 Supplementary Budget Manufacturing, Commercial and Service Innovation Subsidy
  2015
• Chiba City Industrial Promotion Foundation
  Industry-Academia Collaborative Research Promotion Project
  2018–2019, 2022–2023
• Chiba City Industrial Promotion Foundation
  New Product Development Support Project
  2024
• Chiba Industry Advancement Center
  Chiba SME Genki-dukuri Fund Subsidy Project
  2024
• Chiba Prefecture
  Medical Device Development Support Subsidy
  2024–2025
• Chiba Prefecture
  Comprehensive SME Support Program Grant: Regional Innovation Creation Research and Development Grant
  2025–2026
• Small and Medium Enterprise Agency
  The 18th Business Sustainability Subsidy (General Type)
  2026
• Chiba Prefecture
  Approval of Management Innovation Plan
  2023

Team

Get in Touch

Please feel free to contact us using the form below.